1. Home
  2. OCSL vs GERN Comparison

OCSL vs GERN Comparison

Compare OCSL & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Oaktree Specialty Lending Corporation

OCSL

Oaktree Specialty Lending Corporation

HOLD

Current Price

$12.12

Market Cap

1.1B

Sector

Finance

ML Signal

HOLD

Logo Geron Corporation

GERN

Geron Corporation

HOLD

Current Price

$1.29

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OCSL
GERN
Founded
2007
1990
Country
United States
United States
Employees
N/A
229
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.1B
IPO Year
2007
N/A

Fundamental Metrics

Financial Performance
Metric
OCSL
GERN
Price
$12.12
$1.29
Analyst Decision
Hold
Hold
Analyst Count
4
3
Target Price
$12.63
$2.17
AVG Volume (30 Days)
903.7K
15.7M
Earning Date
05-05-2026
05-06-2026
Dividend Yield
12.73%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$26.91
Revenue Next Year
$0.31
$43.75
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.63
$1.04
52 Week High
$14.77
$2.01

Technical Indicators

Market Signals
Indicator
OCSL
GERN
Relative Strength Index (RSI) 47.31 32.86
Support Level $12.07 $1.24
Resistance Level $13.19 $1.49
Average True Range (ATR) 0.28 0.09
MACD -0.09 -0.02
Stochastic Oscillator 15.55 0.00

Price Performance

Historical Comparison
OCSL
GERN

About OCSL Oaktree Specialty Lending Corporation

Oaktree Specialty Lending Corp is a specialty finance company. The company provides lending services and invests in small and mid-sized companies. The company's investment objective is to maximize its portfolio's total return by generating current income from debt investments, and to a lesser extent, capital appreciation from equity investments. The company provides customized, one-stop credit solutions to companies with limited access to public or syndicated capital markets. The company operates as a single reportable segment and derives revenues from investing in originated loans and other securities, including broadly syndicated loans, of U.S. private companies and manages the business on a consolidated basis.

About GERN Geron Corporation

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

Share on Social Networks: